Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suptavumab
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
Suptavumab is a fully human monoclonal antibody developed for the prevention of medically attended lower respiratory tract disease caused by respiratory syncytial virus (RSV), particularly in infants and neonates. It specifically targets the prefusion F-protein epitope of RSV, acting as a viral fusion protein inhibitor to neutralize the virus and prevent infection. Suptavumab demonstrated potent neutralization against RSV-A strains but was less effective against certain mutant RSV-B strains due to amino acid substitutions in the F-protein. The drug was developed by Regeneron Pharmaceuticals and reached Phase 3 clinical trials before development was discontinued after failing to show efficacy in preventing overall RSV hospitalizations or outpatient lower respiratory tract infections[1][4][5][6].
- Other names
- suptavumabREGN-2222REGN2222REGN 2222SAR-438584SAR438584SAR 438584
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on suptavumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suptavumab.